 SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 GLOBE NEWSWIRE -- Aligos Therapeutics, Inc. Nasdaq: ALGS today announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Merck and Aligos will apply Aligos oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis NASH target and up to one additional target of interest in the cardiometabolicfibrosis space. 